No abstract

Candida auris (C. auris) belongs to the Candida genus and is a fungal yeast resistant to multiple drugs. It is highly virulent and evades current therapeutic remedies. It was first discovered in a Japanese hospital in 2009 from a patient's external auditory canal [1] . C. auris infection has a high worldwide mortality, which ranges from 30% to 60%, and is frequently associated with bloodstream infections [2] .The rapid spread of C. auris infection occurred after 2009. The Centers for Disease Control and Prevention (CDC) has estimated the presence of C. auris isolates in 41 countries, typically in hospital settings, as of March 2020 [3] . CDC also reported outbreaks of infections with C. auris in 47 countries globally on February 15, 2021 [4] . The United States reported 2377 clinical cases and 5754 screening cases from January 2022 to December 2022 [5] . Twenty-six isolates of C. auris from India were different genetically and phenotypically from the ones found in Japan and Korea, which provided evidence for C. auris's ability to mutate and its resistance to Azoles [6] .The mechanism of C. auris virulence factors is relatively unknown. According to genomic comparison, C. auris has the ability to adapt to different environments. Two mechanisms of its pathogenesis have been identified, which include hydrolytic enzyme production and attack host cells and tissues. It can also form biofilms that protect it from antifungal drugs and increase its ability in nosocomial transmission [4] .C. auris can be spread in health care facilities such as hospitals and nursing homes through direct patient-to-patient contact. Contaminated surfaces are a significant culprit in the spread when a person comes in contact with them. As C. auris colonizes the skin and can be transmitted into the environment, both properties make it easily transmissible. Population susceptible are immunocompromised people, recently hospitalized patients in areas where C. auris is endemic; catheter use, extended stay in ICU, previous history of antimicrobial exposure, and resistance to antifungal therapy [7] .

Antibiotic resistance has become a critical public health issue due to the overuse and misuse of antibiotics. Despite ongoing efforts to develop stronger antibiotics, bacterial resistance continues to evolve, leading to a global crisis. Effective antibiotics are becoming scarce, and diseases that were once treatable are now becoming uncontrollable. There is a need for new solutions to preserve the current antibiotic arsenal and combat bacterial resistance. Narrow-spectrum antibiotics which do not contribute to multidrug resistance could be a solution instead of broad-spectrum antibiotics. One potential solution is phage therapy, which uses bacteriophages to target specific bacteria without harming healthy cells. Plants are another potential solution because they contain natural antibacterial compounds like polyphenols and alkaloids. Antimicrobial proteins (AMPs) from eukaryotes can also be a good substitute for antibiotics because they do not require a receptor and minimize the chance of bacterial resistance. A clinical trial on women with recurrent UTI was performed. The results of which revealed that overall methenamine hippurate is effective in reducing the intake of antibiotics. Whole genome sequencing is a rapidly evolving method through which resistance pathways are identified to tackle resistance. Developing metallophores is an area of great potential and metal complexes are more likely to advance towards becoming a clinically approved replacement to antibiotics. The development of new solutions is critical to prevent the spread of antibiotic-resistant bacteria and ensure that bacterial infections remain treatable.

Background Hypertension, a leading cause of global mortality and morbidity, affects approximately 1.28 billion adults worldwide, with most cases occurring in low- and middle-income countries. Despite several methods for managing mild to moderate hypertension, effective management of severe or resistant hypertension remains challenging. Renal denervation, a promising non-pharmacological technique, has emerged as a potential solution. Main body Renal denervation works by modifying the renal sympathetic nerve supply through techniques such as ultrasound, radiofrequency energy, or injection of neurolytic agents, reducing blood pressure. Clinical trials, including the RADIANCE series, have shown consistent effectiveness of ultrasound renal denervation in lowering blood pressure, especially in patients who were previously unresponsive to anti-hypertensive medications. After a follow-up of 2 months, mean ambulatory systolic blood pressure during the daytime decreased significantly in the ultrasound renal denervation group compared to the sham group. However, further research is needed to determine renal denervation's long-term safety and efficacy. Conclusions In conclusion, renal denervation holds great potential in improving the treatment of uncontrolled or resistant hypertension treatment, but more investigations and trials are necessary to establish its effectiveness and safety.